INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Indivior PLC Investors (INVVY)

    0
    298
    Reading Time: 2 minutes

    BENSALEM, Pa.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24INVVY&src=ctag” target=”_blank”gt;$INVVYlt;/agt; lt;a href=”https://twitter.com/hashtag/classaction?src=hash” target=”_blank”gt;#classactionlt;/agt;–Law Offices of Howard G. Smith announces that a class action lawsuit has
    been filed on behalf of investors who purchased Indivior PLC (“Indivior”
    or the “Company”) (OTC: INVVY)
    securities between March 10, 2015 and April 9, 2019, inclusive
    (the “Class Period”). Indivior investors have until June 24,
    2019
    to file a lead plaintiff motion.

    Investors suffering losses on their Indivior investments are encouraged
    to contact the Law Offices of Howard G. Smith to discuss their legal
    rights in this class action at 888-638-4847 or by email to [email protected].

    On April 9, 2019, the U.S. Department of Justice (“DOJ”) announced that
    a federal grand jury had indicted Indivior “for engaging in an illicit
    nationwide scheme to increase prescriptions of Suboxone Film, an opioid
    drug used in the treatment of opioid addiction.” According to the
    indictment, Indivior deceived “health care providers and health care
    benefit programs into believing that Suboxone Film was safer, less
    divertible, and less abusable than other opioid-addiction treatment
    drugs,” acquiring billions of dollars in revenue in Suboxone Film
    prescriptions.

    On this news, the Company’s share price fell $4.48 per share, more than
    66%, to close at $2.30 per share on April 10, 2019, on unusually heavy
    trading volume.

    The complaint filed in this class action alleges that throughout the
    Class Period, Defendants made materially false and/or misleading
    statements, as well as failed to disclose material adverse facts about
    the Company’s business, operations, and prospects. Specifically,
    Defendants failed to disclose to investors: (1) Indivior and its
    executives engaged in an illicit nationwide scheme to increase
    prescriptions of Suboxone Film; (2) Indivior illegally obtained billions
    of dollars in revenue from Suboxone Film prescriptions by deceiving
    health care providers and health care benefit programs; (3) as a result,
    Indivior would face felony charges; and (4) due to the foregoing,
    defendants’ statements about its business, operations, and prospects,
    were materially false and misleading and/or lacked a reasonable basis at
    all relevant times.

    If you purchased shares of Indivior, have information or would like to
    learn more about these claims, or have any questions concerning this
    announcement or your rights or interests with respect to these matters,
    please contact Howard G. Smith, Esquire, of Law Offices of Howard G.
    Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by
    telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected],
    or visit our website at www.howardsmithlaw.com.

    This press release may be considered Attorney Advertising in some
    jurisdictions under the applicable law and ethical rules.

    Contacts

    Law Offices of Howard G. Smith
    Howard G. Smith, Esquire
    215-638-4847
    888-638-4847
    [email protected]
    www.howardsmithlaw.com